Stockreport

Mustang Bio Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR-T Therapy [Y...

Mustang Bio, Inc.  (MBIO) 
Last mustang bio, inc. earnings: 11/12 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: mustangbio.com/investor-relations
PDF All patients were heavily pretreated/refractory to BTK inhibitors, and only one patient has started new anti-WM treatment after MB-106 Outpatient administration was a [Read more]